The technology is a new method for identifying and cloning novel cancer antigens. Unlike earlier methods for cloning cancer antigens, this method does not require prior knowledge of which MHC fragments should be used to ensure recognition by Th cells and can be directly used to develop new antigens for cancer vaccines and diagnostics.

This technology is protected by International PCT Application WO 2006/138449 A2, “Method for Identifying a MHC Class II-Dependent Tumor-Associated T Helper Cell Antigen” (Herlyn, D.; Somasundaram, R.; Swoboda, R.; December 28, 2006).

U.S. Patent Application No. 11/917,363 (US-2010-0080792, published 04/01/2010).

Swoboda et al.; 2007. “Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display”. Cancer Res 67: 3555-3559